---
schema_version: "secwatch.filing_event.v1"
accession: "0001178253-25-000006"
form_type: "8-K"
ticker: "SCYX"
cik: "0001178253"
company_name: "SCYNEXIS INC"
filed_at: "2025-10-15T23:59:59+00:00"
generated_at: "2026-05-17T03:41:15.644206+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# SCYNEXIS resolves MARIO study dispute with GSK, receives $22M payment

## Summary
- Binding MOU terminates Phase 3 MARIO trial for invasive candidiasis; SCYNEXIS gets $22M from GSK.
- Additional $2.3M payment from GSK for wind-down and termination activities.
- SCYNEXIS will transfer BREXAFEMME NDA to GSK by end of 2025; GSK plans FDA interactions in 2026 for VVC/rVVC relaunch.
- Milestones and royalties for VVC and rVVC indications remain unchanged under the exclusive license agreement.

## SEC filing metadata
- accession: 0001178253-25-000006
- form_type: 8-K
- ticker: SCYX
- cik: 0001178253
- company_name: SCYNEXIS INC
- filed_at: 2025-10-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178253/000117825325000006/0001178253-25-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178253/000117825325000006/scyx-20251014.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178253-25-000006
- JSON: https://secwatch.observer/filing/0001178253-25-000006.json
- Plain text: https://secwatch.observer/filing/0001178253-25-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.